Abstracts tagged "Psoriasis and safety"

Abstract Number: 1503 • 2019 ACR/ARP Annual Meeting
Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
Mark Genovese¹, Hideto Kameda ², Proton Rahman ³, Juan Cañete ⁴, Sandra Garces ⁵, Wen Xu ⁶, Matthew M. Hufford ⁵ and Bernard Combe ⁷, ¹Stanford University, Stanford, CA, ²Toho University, Tokyo, Japan, Tokyo, Japan, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that specifically targets IL-17A. Pooled safety data from IXE studies in moderate-to-severe plaque psoriasis (PsO) and psoriatic…
Abstract Number: 1690 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results
Kristian Reich¹, Jennifer Soung², Melinda Gooderham³, Zuoshun Zhang⁴, Kristine Nograles⁴, Robert M. Day⁴, Laura Ferris⁵ and Mark Goodfield⁶, ¹SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, ²Southern California Dermatology, Santa Ana, CA, ³SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada, ⁴Celgene Corporation, Summit, NJ, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Department of Dermatology, Leeds Centre for Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Psoriasis is a chronic systemic inflammatory disease often treated with conventional systemic and biologic drugs that may variously be ineffective, be inaccessible, or pose…